LENZ Therapeutics reported second quarter 2026 financial results on August 11, 2026. Total revenue was $5.5 million, comprising $1.7 million in product sales from approximately 27,000 packs of VIZZ and $3.8 million in license revenue, which included a $2.5 million regulatory milestone under the Théa agreement and $1.25 million in sublicense revenue from Everest Medicines for Greater China rights. The company reported a net loss of $31.9 million, or $1.02 per share, compared to a $14.9 million loss in the prior year period. Selling, general, and administrative expenses rose to $39.4 million due to launch investments in marketing and sales infrastructure. Cash, cash equivalents, and marketable securities totaled $220.0 million as of June 30, 2026. LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ for the treatment of presbyopia.

Zach Scheiner resigned from the Board of Directors and all its committees effective June 30, 2026, without any disagreement with the Company. The Board size was subsequently reduced to six members, and Jeff George was appointed to the Audit Committee. LENZ Therapeutics, Inc. is a biotechnology company focused on ophthalmic therapies.